“Blood Screening market set to represent exceeding CAGR by 2029” says new Visiongain report

04 September 2019
Pharma

Visiongain has launched a new pharma report Blood Screening Market Forecast 2019-2029: By Technology (NAT, ELISA, CLIA, NGS, Western Blotting) & By Product (Reagents, Instruments) Segments.

The growth of the global blood screening market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Moreover, there is ever increasing demand for blood screening tests due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Also, governments across the countries are in process to mandates testing all donated blood for several viruses.

Blood donation requires the blood to be free from disease causing agents namely HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). This is done to decrease the chances of transfusion-transmitted contaminations (TTIs).

With continuous technological advancement in this segment, especially the U.S. FDA approved next-generation sequencing (NGS) technology in 2013 has made the blood screening cheaper and faster than previous DNA analysis methods has done well for the industry. The worldwide blood screening market is witnessing technological advancements with respect to devices and utilities involved in blood donation centres and doctor’s facilities for the screening of different TTIs.

Leading companies featured in the report include Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary Of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary Of Danaher Corporation), Becton, Dickinson And Company.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

 

Recent News

The Global Wound Care Market Is Set to Boom, Particularly in Emerging Economies

The global wound care market is big, and only set to grow bigger.  Currently, estimates show a CAGR of 4.6% in the years to come, with the overall market growing from US$19.8 billion in 2019 to US$24.8 billion by 2024.  The industry is ripe with opportunity, with that growth coming from several factors – but most especially growth in emerging …

30 March 2020

Read

“The global nasal drug delivery technology market is estimated to have reached $44,385 million in 2019” says new Visiongain report

Nasal Sprays segment held the largest market share of the global nasal drug delivery technology market in 2019.

30 March 2020

Read

“Global Stem Cell Technologies and Applications market set to grow to $10903.0m by 2025” says new Visiongain report

New technologies will be needed to ensure that scaling-up of manufacturing operations can be done effectively once stem cell treatments enter the market.

24 March 2020

Read

Visiongain publishes Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030 report

As per the latest reports of UNCTAD (United Nations Conference on Trade and Development), COVID-19 pandemic has not only led to tragic human consequences but is projected to cost the global economy $1 trillion in 2020.

24 March 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever